GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.
Yao Li, Xiaoou Xu, Adili Tuersun et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the efficacy and safety of GLP-1 receptor agonists (GLP-1RAs) in adolescents with obesity, analyzing 17 randomized clinical trials involving 1230 participants. Semaglutide 2.4 mg SC was found to produce the largest reductions in body weight (mean difference -18.00 kg) and BMI (-5.9 kg/m²), while dulaglutide 1.5 mg SC showed the greatest reduction in HbA1c (-1.50%).
Key findings
- Semaglutide 2.4 mg SC led to a mean weight reduction of -18.00 kg.
- Dulaglutide 1.5 mg SC resulted in a reduction of HbA1c by -1.50%.
- Lixisenatide 20 µg SC showed a decrease in fasting plasma glucose of -3.98 mmol/L.
- Exenatide 20 µg SC was associated with a reduction in systolic blood pressure of -6.64 mmHg.
Why it matters
Understanding the differential effects of GLP-1RAs on cardiometabolic outcomes in adolescents with obesity can guide clinicians in selecting appropriate therapies to optimize patient management and improve health outcomes.
What to keep in mind
Many active-treatment comparisons were indirect, and several nodes were informed by single trials, limiting the strength of conclusions.